The Food and Drug Administration’s emergency use authorization of convalescent plasma as a treatment for COVID-19 is not sitting well with some infectious disease specialists.
The head of the Infectious Disease Society of America says we still lack the “randomized controlled trial data we need to better understand its utility in COVID-19 treatment.” President Trump had earlier accused the FDA of purposely delaying the serum’s release for political reasons.
Rochelle Walensky is chief of infectious disease at Massachusetts General Hospital and joins host Peter O’Dowd to explain the treatment and the FDA decision.
This article was originally published on WBUR.org.
Copyright 2020 NPR. To see more, visit https://www.npr.org. 9(MDA5MTc0MDI0MDEzMzE4MjI4ODdlOTk4MA004))